LLYC Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Eli Lilly and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$711.10 |
| 52 Week High | US$885.10 |
| 52 Week Low | US$517.00 |
| Beta | 0.43 |
| 11 Month Change | -15.28% |
| 3 Month Change | -15.98% |
| 1 Year Change | 29.53% |
| 33 Year Change | 203.50% |
| 5 Year Change | 567.32% |
| Change since IPO | 626.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| LLYC | AT Pharmaceuticals | AT Market | |
|---|---|---|---|
| 7D | -7.9% | -3.2% | -0.2% |
| 1Y | 29.5% | 3.2% | 2.3% |
Return vs Industry: LLYC exceeded the Austrian Pharmaceuticals industry which returned 4.3% over the past year.
Return vs Market: LLYC exceeded the Austrian Market which returned 1.2% over the past year.
Price Volatility
| LLYC volatility | |
|---|---|
| LLYC Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in AT Market | 6.5% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: LLYC's share price has been volatile over the past 3 months compared to the Austrian market.
Volatility Over Time: LLYC's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
| LLYC fundamental statistics | |
|---|---|
| Market cap | €647.19b |
| Earnings (TTM) | €7.98b |
| Revenue (TTM) | €38.98b |
80.7x
P/E Ratio16.5x
P/S RatioIs LLYC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LLYC income statement (TTM) | |
|---|---|
| Revenue | US$40.86b |
| Cost of Revenue | US$7.80b |
| Gross Profit | US$33.06b |
| Other Expenses | US$24.69b |
| Earnings | US$8.37b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.30 |
| Gross Margin | 80.91% |
| Net Profit Margin | 20.48% |
| Debt/Equity Ratio | 218.1% |
How did LLYC perform over the long term?
See historical performance and comparisonDividends
0.7%
Current Dividend Yield54%
Payout RatioDoes LLYC pay a reliable dividends?
See LLYC dividend history and benchmarks| Eli Lilly dividend dates | |
|---|---|
| Ex Dividend Date | Nov 15 2024 |
| Dividend Pay Date | Dec 10 2024 |
| Days until Ex dividend | 7 days |
| Days until Dividend pay date | 18 days |
Does LLYC pay a reliable dividends?
See LLYC dividend history and benchmarks